Selenium and androgen receptor in prostate cancer

Androgen Action in Prostate Cancer

Volumn , Issue , 2009, Pages 755-780

  Nadiminty, Nagalakshmi ^b   Gao, Allen C ^a  

^a Research III   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868101019     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69179-4_33     Document Type: Chapter

References (166)

1. Aarnisalo P, Palvimo JJ, Janne OA (1998) CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA. 95: 2122-2127.
2. Abreu-Martin MT, Chari A, Palladino AA, et al. (1999) Mitogen activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 19: 5143-5144.
3. Alexander J (2007) Selenium. Novartis Found Symp 282: 143-149.
4. Allen NE, Morris JS, Ngwenyama RA, et al. (2004) A case-control study of selenium in nails and prostate cancer risk in British men. J Cancer 90(7): 1392-1396.
5. Al-Taie OH, Suefert J, Mork H, et al. (2002) A complex DNA-repeat structure within the selenoprotein P promoter contains a functionally relevant polymorphism and is genetically unstable under conditions of mismatch repair deficiency. Eur J Hum Genet 10(9): 499-504.
6. Asim M, Siddiqui IA, Hafeez BB, et al. (2008) Src kinase potentiates androgen receptor transac-tivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene (EPub) 1-9.
7. Brooks JD, Metter EJ, Chan DW, et al. (2001) Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166: 2034-2038.
8. Calvo A, Xiao N, Kang J, et al. (2002) Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of seleno-protein-P in mouse and human tumors. Cancer Res 62(18): 5325-5335.
9. Chan JM, Stampfer MJ, Giovanucci E, et al. (1998) Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 279: 563-566.
10. Chatterjee B (2003) The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 253(1-2): 89-101.
11. Chen SD, Welsbie DS, Tran C, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
12. Chmelar R, Buchanan G, Need EF, et al. (2006) Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120: 719-733.
13. Cho SD, Jiang C, Malewicz B, et al. (2004) Methyl selenium metabolites decrease prostate specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 3(5): 605-611.
14. Christensen MJ, Nartey ET, Hada AL, et al. (2007) High selenium reduces NF-kappaB-regulated gene expression in uninduced human prostate cancer cells. Nutr Cancer 58(2): 197-204.
15. Chun JY, Nadiminty N, Lee SO, et al. (2006) Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Mol Cancer Ther 5(4): 913-918.
16. Clark LC, Jacobs ET (1998) Environmental selenium and cancer: risk or protection? Cancer Epidemiol Biomarkers Prev 7(10): 847-848.
17. Clark LC, Marshall JR (2001) Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: elevated prostate specific antigen and high-grade prostatic intraepithelial neoplasia. Urology 57: 185-187.
18. Clark LC, Combs GF Jr, Turnbull BW, et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276(24): 1957-1963.
19. Clark LC, Dalkin B, Krongrad A, et al. (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81(5): 730-734.
20. Combs GF Jr (2001) Considering the mechanisms of cancer prevention by selenium. Adv Exp Med Biol 492: 107-117.
21. Combs GF (2004) Status of selenium in prostate cancer prevention. Br J Cancer 91: 195-199.
22. Combs GF Jr, Combs SB (1984) The nutritional biochemistry of selenium. Annu Rev Nutr 4: 257-280.
23. Combs GF, Gray WP (1998) Chemopreventive agents:selenium. Pharmacol Ther 79: 179-192.
24. Combs GF, Clark LC, Turnbull BW (1997) Reduction of cancer risk with an oral supplement of selenium. Biomed Environ Sci 10(2-3): 227-234.
25. Corcoran NM, Najdovska M, Costello AJ (2004) Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 171: 907-910.
26. Costello AJ (2001) A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: Rationale, recruitment and design issues. Urology 57(4A): 182-184.
27. Craft N, Shostak K, Carey M, et al. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
28. Culig Z, Hobisch A, Cronauer MV, et al. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 54: 5474-5478.
29. D'amico F, Biancolella M, Margiotti K, et al. (2007) Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics 8(6): 645-661.
30. de Jong FH, Reuvers PJ, Bolt-de Vries J, et al. (1992) Androgens and androgen receptors in prostate tissue from patients with benign prostatic hyperplasia: effects of cyproterone acetate. J Steroid Biochem Mol Biol 52: 49-55.
31. Dewaily E, Mulvad G, Sloth Pedersen H, et al. (2003) Inuit are protected against prostate cancer. Cancer Epidemiol Biomarkers Prev 12(9): 926-927.
32. Diwadkar-Navsariwala V, Prins GS, Swanson SM, et al. (2006) Selenoprotein.deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci USA 103: 8179-8184.
33. Dong Y, Zhang H, Hawthorn L, et al. (2003) Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 63(1): 52-59.
34. Dong Y, Lee SO, Zhang H, et al. (2004) Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 64(1): 19-22.
35. Dong Y, Zhang H, Gao AC, et al. (2005) Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther 4(7): 1047-1055.
36. Drake EN (2006) Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Med Hypotheses 67(2): 318-322.
37. Drasch G, Mail der S, Schlosser C, et al. (2000) Content of non-mercury associated selenium in human tissues. Biol Trace Elem Res 77: 219-230.
38. Duffield AJ, Thomson CD, Hill KE, et al. (1999) An estimation of selenium requirements for New Zealanders. Am J Clin Nutr 70: 896-903.
39. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. (2003) Nutritional Prevention of Cancer Study group, Selenium-supplementation, baseline plasma selenium levels and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91(7): 608-612.
40. El-Bayoumy K, Sinha R (2005) Molecular chemoprevention by selenium: A genomic approach. Mutat Res 591: 224-236.
41. Eng J, Ramsum D, Verhoef M, et al. (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2(3): 212-216.
42. Fu M, Wang C, Wang J, et al. (2002) Androgen receptor acetylation governs transactivation and MEKK-1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 22: 3373-3388.
43. Fu M, Wang C, Li Z, et al. (2004) Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology 145(12): 5439-5447.
44. Gasparian AV, Yao YJ, Lu J, et al. (2002) Selenium compounds inhibit IkappaB kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. Mol Cancer Ther 1(12): 1079-1087.
45. Ghosh J (2004) Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophy Res Commun 315: 624-635.
46. Gianduzzo TR, Holmes EG, Tinggi U, et al. (2003) Prostatic and peripheral blood selenium levels after oral supplementation. J Urol 170(3): 870-873.
47. Goodman GE, Schaffer S, Bankson DD, et al. & the Carotene and Retinol Efficacy Trial (CARET) Co-investigators (2001) Predictors of serum in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 10: 1069-1076.
48. Grossmann ME, Huang H, Tindall TJ (2001) Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst 22: 1687-1697.
49. Haapala K, Kuukasjarvi T, Hyytinen E, et al. (2007) Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 38: 474-478.
50. Harada S, Keller ET, Fujimoto N, et al. (2001) Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate 46: 319-326.
51. Helzslouer KJ, Huang H-Y, Alberg AJ, et al. (2000) Association between alpha-tocopherol, gamma-tocopherol, selenium and subsequent prostate cancer. J Natl Cancer Inst 92: 2018-2023.
52. Hobisch A, Eder IE, Putz T, et al. (1998) Interleukin-6 regulates prostate specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640-4645.
53. Hu YJ, Korotkov KV, Mehta R, et al. (2001) Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res 61(5): 2307-2310.
54. Hu H, Jiang C, Li G, et al. (2005) PKB/Akt and Erk regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis 26(8): 1374-81.
55. Hu H, Jiang C, Schuster T, et al. (2006) Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax- mediated activation of the mitochon-drial pathway. Mol. Cancer Ther 5(7): 1873-1882.
56. Husbeck B, Peehl DM, Knox SJ (2005) Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med 38(1): 50-57.
57. Husbeck B, Bhattacharya RS, Feldman D, et al. (2006a) Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther 5(8): 2078-2085.
58. Husbeck B, Nonn L, Peehl DM, et al. (2006b) Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66(2): 218-225.
59. Ip C (1998) Lessons from basic research in selenium and cancer prevention. J Nutr 128: 1845-1854.
60. Ip C, Thompson HJ, Zhu Z, et al. (2000) In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60(11): 2882-2886.
61. Javidan J, Deitch A, Shi XB, et al. (2005) The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invest 23(6): 520-528.
62. Jiang C, Jiang W, Ip C, et al. (1999) Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 26(4): 213-225.
63. Jiang C, Ganther H, Lu J (2000a) Monomethylselenium-specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 29(4): 236-250.
64. Jiang C, Wang Z, Ganther H, et al. (2000b) Caspases as key regulators of methyl selenium-induced apoptosis (anoikis) of DU 145 prostate cancer cells. Cancer Res 61(7): 3062-3070.
65. Jin RJ, Wang Y, Masumori N, et al. (2004) NE-10 neuroendocrine cancer promotes the LNCaP xenografts growth in castrated mice. Cancer Res 64: 5489-5495.
66. Kaarbo M, Klokk TI, Saatcioglu F (2007) Androgen signaling and its interactions with other signaling pathways in prostate cancer. BioEssays 29: 1227-1238.
67. Karin M, Cao Y, Greten FR, et al. (2002) NF-kappaB in cancer: from innocent by-stander to major culprit. Nature Rev Cancer 2: 301-310.
68. Karunasinghe N, Ryan J, Tuckey J, et al. (2004) DNA stability and serum selenium levels in a high risk group for prostate cancer. Cancer Epidemiol Biomarkers Prev 13(3): 391-397.
69. Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3(4): 513-519.
70. Klein EA (2004) Selenium and Vitamin E cancer prevention trial. Ann NY Acad Sci 1031: 234-41.
71. Klein EA, Thompson IM (2004) Update on chemoprevention of prostate cancer. Curr Opin Urol 14: 143-149.
72. Knekt P, Aromaa A, Maatela J, et al. (1990) Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 82: 864-868.
73. Konishi N, Shimada K, Ishida E, et al. (2005) Molecular pathology of cancer. Pathol Int 55: 531-539.
74. Korotkov KV, Kumaraswamy E, Zhou Y, et al. (2001) Association between the 15-kDa seleno-protein and UDP-glucose:glycoprotein glucosyltransferase in the endoplasmic reticulum of mammalian cells. J Biol Chem 276(18): 15330-15336.
75. Kranse R, Dagnelie PC, van Kemenade M, et al. (2005) Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer 113(5): 835-840.
76. Kryukov GV, Castellano S, Novoselov SV, et al. (2003) Characterization of mammalian seleno-proteomes. Science 300: 1439-1443.
77. Kumaraswamy E, Malykh A, Korotkov KV, et al. (2000) Structure-expression relationships of the 15 kDa selenoprotein gene. Possible role of the protein in cancer etiology. J Biol Chem 275(45): 35540-35547.
78. Lee SO, Chun JY, Nadiminty N, et al. (2006) Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenografts accompanied by a decrease in the expression of androgen receptor and prostate specific antigen (PSA). Prostate 66(10): 1070-1075.
79. Li H, Stampfer MJ, Giovanucci EL, et al. (2004) A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 96: 696-703.
80. Li G-X, Hu H, Jiang C, et al. (2007) Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int J Cancer 120: 2034-2043.
81. Liao Y, Abel U, Grobholz R, et al. (2005) Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Human Pathology 36: 1186-1196.
82. Lipsky K, Zigeuner R, Zischka M, et al. (2004) Selenium levels of patients with newly diagnosed prostate cancer compared with control group. Urology 63(5): 912-916.
83. Lorenzo GD, Bianco R, Tortora G, et al. (2003) Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer 2: 50-57.
84. Marshall JR (2001) Larry Clark's legacy: randomized controlled, selenium-based prostate cancer chemoprevention trials. Nutr Cancer 40(1): 74-77.
85. Marshall JR, Sakr W, Wood D, et al. (2006) Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 15(8): 1479-1484.
86. McLeod DG, Srivastava S (2006) Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 25(28): 3905-3913.
87. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565.
88. Menter DG, Sabichi AL, Lippman SM (2000) Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9(11): 1171-1182.
89. Meuillet E, Stratton S, Cherukuri DP, et al. (2004) Chemoprevention of prostate cancer with selenium: An update on current clinical trials and preclinical findings. J Cell Biochem 91: 443-458.
90. Mohler JL, Gregory CW, Ford OHIII, et al. (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res 10(2): 440-448.
91. Montgomery B, Mostaghel E, Vessella R, et al. (2007) Androgen synthesis in castration-adapted metastatic prostate cancer. ASCO Meeting 2007: Orlando, Florida, USA, 22-24 February (Abstract No. 98).
92. Morris JD, Pramanik R, Zhang X, et al. (2006) Selenium-or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen receptor activity. Cancer Lett 239(1): 111-122.
93. Moscow JA, Schmidt L, Ingram DT, et al. (1994) Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis 15(12): 2769-2773.
94. Navarro-Silvera SA, Rohan TE (2007) Trace elements and cancer risk: a review of the epidemio-logic evidence. Cancer Causes Control 18: 7-27.
95. Nieto M, Finn S, Loda M, et al. (2007) Prostate cancer: Re-focusing on androgen receptor signaling. The Intl J of Biochem Cell Biol 39: 1562-1568.
96. Ni J, Chen M, Zhang Y, et al. (2003) Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 300 (2): 357-363.
97. Nomura AM, Lee J, Stemmermann GN, et al. (2000) Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 9: 883-887.
98. Novoselov SV, Kryukov GV, Xu XM, et al. (2007) Selenoprotein H is a nuclear thioredoxin-like protein with a unique expression pattern. J Biol Chem 282(16): 11960-11968.
99. Nyman DW, Stratton SM, Kopplin MJ, et al. (2004) Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev 28(1): 8-16.
100. Ohta Y, Suzuki KT (2008) Methylation and demethylation of intermediates selenide and methyl-selenol in the metabolism of selenium. Toxicol. Appl. Pharmacol. 226(2): 169-177.
101. Pak RW, Lanteri VJ, Scheuch JR, et al. (2002) Review of vitamin E and Selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integr Cancer Ther 1(4): 338-344.
102. Patrick L (2004) Selenium biochemistry and cancer: A review of the literature. Altern Med Rev 9 (3): 239-258.
103. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12(6): 1665-1671.
104. Pinto JT, Sinha R, Papp K, et al. (2007) Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells. Int J Cancer 120: 1410-1417.
105. Ramachandran K, Navarro L, Gordian E, et al. (2007) Methylation-mediated silencing of genes is not altered by selenium treatment of prostate cancer cells. AntiCancer Res 27(2): 921-925.
106. Rayman MP (2000) The importance of selenium to human health. Lancet 356: 233-241.
107. Ravn-Haren G, Bugel S, Krath BN, et al. (2007) A short-term intervention trial with selenate, selenium-enriched yeast and selenium-enriched milk: effects on oxidative defence regulation. Br J Nutr Sep 21, 1-10.
108. Rayman MP (2005) Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 64: 527-542.
109. Rebsch CM, Penna FJ, Copeland PR (2006) Selenoprotein expression is regulated at multiple levels in prostate cells. Cell Res 16(12): 940-948.
110. Reddy GP, Barrack ER, Dou QP, et al. (2006) Regulatory processes affecting androgen receptor expression, stability and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98: 1408-1423.
111. Reid ME, Stratton MS, Lillico A, et al. (2004) A report of high dose selenium supplementation: Response and toxicities. J Trace Elem Biol Med 18: 69-74.
112. Ryan-Harshman M, Aldoori W (2005) The relevance of selenium to immunity, cancer, and infectious/inflammatory diseases. Can J Diet Pract Res 66(2): 98-102.
113. Sabichi AL, Lee JJ, Taylor RJ, et al. (2006) Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of L-selenomethionine: a Southwest Oncology Group study. Clin Cancer Res 12(7): 2178-2184.
114. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting androgen receptor signaling axis. J Clin Oncol 23(32): 8253-8261.
115. Schlicht M, Matysiak B, Brodzeller T, et al. (2004) Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium. BMC Genomics 5: 58-69.
116. Schroder FH (2008) Progress in understanding androgen-independent prostate cancer (AIPC): A review of potential endocrine-mediated mechanisms. Eur Urol doi:10.1016/j.eururo. 2008.01.049.
117. Schweizer L, Rizzo CA, Spires TE, et al. (2008) The androgen receptor can signal through Wnt/b-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol 9:4.
118. Schrauzer GN, White DA, Schneider CJ (1977a) Cancer mortality correlation studies-III: statistical associations with dietary selenium intakes. Bioinorganic Chem 7(1): 23-31.
119. Schrauzer GN, White DA, Schneider CJ (1977b) Cancer mortality correlation studies-IV: associations with dietary intakes and blood levels of certain trace elements, notably Se-antagonists. Bioinorganic Chem 7(1): 35-56.
120. Shamberger RJ, Frost DV (1969) Possible protective effect of selenium against human cancer. Can Med Assoc J 100(14): 682-692.
121. Singh RP, Agarwal R (2006) Mechanisms of action of novel agents for prostate cancer chemopre-vention. Endocr Related Cancer 13: 751-778.
122. Sommer A, Haendler B (2003) Androgen receptor and prostate cancer: molecular aspects and gene expression profiling. Curr Opin Drug Discov Devel 6(5): 702-711.
123. Spallholz JE (1994) On the nature of selenium toxicity and carcinostatic activity. Free Radic Biol Med 17: 45-64.
124. Squires J, Berry MJ (2006) Selenium, Selenoproteins and cancer. Hawaii Med J 65(8): 239-240.
125. Stanbrough M, Bubley GJ, Ross K, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
126. Stratton MS, Reid ME, Schwartzberg G, et al. (2003a) Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy study. Anticancer Drugs 14(8): 589-594.
127. Stratton MS, Reid ME, Schwartzberg G, et al. (2003b) Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the "Watchful Waiting" study. Anticancer Drugs 14(8): 595-600.
128. Suh J, Rabson AB (2004) NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 91: 100-117.
129. Syed DN, Khan N, Afaq F, et al. (2007) Chemoprevention of prostate cancer through dietary agents: Progress and promise. Cancer Epidemiol Biomarkers Prev 16(11): 2193-2203.
130. Syed S, Tolcher A (2003) Innovative therapies for prostate cancer treatment. Rev Urol 5 (suppl 3): S78-84.
131. Takaha N, Resar LM, Vindivich D, et al. (2004) High mobility group protein HMGI(Y) enhances tumor cell growth, invasion and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 60: 160-167.
132. Taplin M-E (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nature Clin Pract Oncol 4(4): 236-244.
133. Taplin ME, Rajeshkumar B, Halabi S, et al. (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and leukemia group study 1993. J Clin Oncol 21: 2673-2678.
134. Terry S, Yang X, Chen MW, et al. (2006) Multifaceted interaction between the androgen receptor and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 99: 402-410.
135. Thompson IM (2007) Chemoprevention of prostate cancer: Agents and study designs. J Urol 178 (3): S9-S13.
136. Thomson CD, Robinson MF, Butler JA, et al. (1993) Long term supplementation with selenate and selenomethionine: selenium and glutathione peroxidase (EC 1.11.1.9) in blood components of New Zealand women. Br J Nutr 69: 577-588.
137. Titus MA, Schell MJ, Lih FB, et al. (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11(13): 4653-4657.
138. Ueda T, Bruchovsky N, Sadar MD (2002) Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and Stat3 signal transduction pathways. J Biol Chem 277: 7076-7085.
139. Unni E, Sun S, Nan B, et al. (2004) Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64: 7156-7168.
140. Uzgare AR, Kapaln PJ, Greenberg NM (2003) Differential expression and/or activation of p38MAPK, erk1/2, and jnk in the initiation and progression of prostate cancer. Prostate 55: 128-139.
141. Vadgama JV, Wu Y, Shen D, et al. (2000) Effect of selenium in combination with adriamycin or taxol on several different cancer cells. Anticancer Res 20(3A): 1391-1414.
142. van den Brandt PA, Zeegers MP, Bode P, et al. (2003) Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 12: 866-871.
143. Vander Griend DJ, Litvinov IV, Isaacs JT (2007) Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 6(6): 647-651.
144. Venkateswaran V, Fleshner NE, Sugar LM, et al. (2004) Antioxidants block prostate cancer in Lady transgenic mice. Cancer Res 64(16): 5891-5896.
145. Vogt TM, Ziegler RG, Patterson BH, et al. (2007) Racial differences in serum selenium concentration: Analysis of US population data from the Third National Health and Nutrition Examination survey. Am J Epidemiol 166(3): 280-288.
146. Wang Z, Jiang C, Lu J (2002) Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 34(3): 113-120.
147. Wang Z, Hu H, Li G, et al. (2008) Methylseleninic acid inhibits microvascular endothelial G(1) cell cycle progression and decreases tumor microvessel density. Int J Cancer 122: 15-24.
148. Waters DJ, Shen S, Cooley DM, et al. (2003) Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 95(3): 237-241.
149. Whanger PD (2002) Selenocompounds in plants and animals their biological significance. J Am Coll Nutr 21: 223-232.
150. Whanger P, Vendeland S, Park YC, et al. (1996) Metabolism of subtoxic levels of selenium in animals and humans. Ann Clin Lab Sci 26: 99-113.
151. World Health Organization. (1987) Selenium, Geneva World Health Organization, Environmental Health Criteria 58.
152. Wu Y, Zhang H, Dong Y, et al. (2005) Endoplasmic reticulum stress signal mediators are targets of selenium action. Cancer Res 65(19): 9073-9079.
153. Xia Y, Hill KE, Byrne DW, et al. (2005) Effectiveness of selenium supplements in a low selenium area of China. Am J Clin Nutr 81: 829-834.
154. Yang SZ and Abdulkadir SA (2003) Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells. J Biol Chem 278(41): 39906-39911.
155. Yang L, Wang L, Lin HK, et al. (2003) Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, Stat3 and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 305: 462-465.
156. Yang X, Chen MW, Terry S, et al. (2006) Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25: 3436-3444.
157. Yoshizawa K, Willett WC, Morris SJ, et al. (1998) Study of prediagnostic selenium levels in toenails and the risk of prostate cancer. J Natl Cancer Inst 90:1219-1224.
158. Yu SY, Chu YJ, Li WG (1988) Selenium chemoprevention of liver cancer in animals and possible human applications. Biol Trace Elem Res 15: 231-241.
159. Yu YP, Yu G, Tseng G, et al. (2007) Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 67(17): 8043-8050.
160. Zachara BA, Szewczyk-Golec K, Tyloch J, et al. (2005a) Blood and tissue selenium concentrations and glutathione peroxidase activities in patients with prostate cancer and benign prostate hyperplasia. Neoplasma 52(3): 248-254.
161. Zachara BA, Szewczyk-Golec K, Wolski Z, et al. (2005b) Selenium level in benign and cancerous prostate. Biol Trace Elem Res 103(3): 199-206.
162. Zhao H and Brooks JD (2007) Selenomethionine induced transcriptional programs in human prostate cancer cells. J Urol 177: 743-750.
163. Zhao H, Whitfield ML, Xu T, et al. (2004) Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell 15(2): 506-519.
164. Zhao R, Domann FE, Zhong W (2006) Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol Cancer Ther 5 (1): 3275-3284.
165. Zu K, Ip C (2003) Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 63 (20): 6988-6995.
166. Zu K, Bihani T, Lin A, et al. (2006) Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 25(4): 546-554.